218 related articles for article (PubMed ID: 30828771)
1. Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.
Mikus G; Foerster KI; Schaumaeker M; Lehmann ML; Burhenne J; Haefeli WE
Clin Pharmacokinet; 2019 Sep; 58(9):1155-1163. PubMed ID: 30828771
[TBL] [Abstract][Full Text] [Related]
2. Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers.
Rohr BS; Krohmer E; Foerster KI; Burhenne J; Schulz M; Blank A; Mikus G; Haefeli WE
Clin Pharmacokinet; 2024 Apr; 63(4):469-481. PubMed ID: 38393578
[TBL] [Abstract][Full Text] [Related]
3. Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.
Goto E; Horinaka S; Ishimitsu T; Kato T
Drug Metab Pharmacokinet; 2020 Feb; 35(1):151-159. PubMed ID: 32007354
[TBL] [Abstract][Full Text] [Related]
4. Application of a microdosed cocktail of 3 oral factor Xa inhibitors to study drug-drug interactions with different perpetrator drugs.
Mikus G; Foerster KI; Schaumaeker M; Lehmann ML; Burhenne J; Haefeli WE
Br J Clin Pharmacol; 2020 Aug; 86(8):1632-1641. PubMed ID: 32159869
[TBL] [Abstract][Full Text] [Related]
5. Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method.
Zhang WL; Lou D; Zhang DT; Zhang Y; Huang HJ
J Thromb Thrombolysis; 2016 Aug; 42(2):205-11. PubMed ID: 27116356
[TBL] [Abstract][Full Text] [Related]
6. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.
Kreutz R; Persson PB; Kubitza D; Thelen K; Heitmeier S; Schwers S; Becka M; Hemmrich M
J Thromb Haemost; 2017 Oct; 15(10):2017-2028. PubMed ID: 28805299
[TBL] [Abstract][Full Text] [Related]
7. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
Frost CE; Byon W; Song Y; Wang J; Schuster AE; Boyd RA; Zhang D; Yu Z; Dias C; Shenker A; LaCreta F
Br J Clin Pharmacol; 2015 May; 79(5):838-46. PubMed ID: 25377242
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital.
Yamazaki-Nishioka M; Kogiku M; Noda M; Endo S; Takekawa M; Kishi H; Ota M; Notsu Y; Shimizu M; Yamazaki H
Xenobiotica; 2019 Sep; 49(9):1001-1006. PubMed ID: 30216091
[TBL] [Abstract][Full Text] [Related]
9. Perpetrator Characteristics of Azole Antifungal Drugs on Three Oral Factor Xa Inhibitors Administered as a Microdosed Cocktail.
Rohr BS; Foerster KI; Blank A; Burhenne J; Mahmoudi M; Haefeli WE; Mikus G
Clin Pharmacokinet; 2022 Jan; 61(1):97-109. PubMed ID: 34273071
[TBL] [Abstract][Full Text] [Related]
10. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
Parasrampuria DA; Mendell J; Shi M; Matsushima N; Zahir H; Truitt K
Br J Clin Pharmacol; 2016 Dec; 82(6):1591-1600. PubMed ID: 27530188
[TBL] [Abstract][Full Text] [Related]
11. Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A.
Otsuka Y; Choules MP; Bonate PL; Komatsu K
CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):659-669. PubMed ID: 33030266
[TBL] [Abstract][Full Text] [Related]
12. A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation.
Willekens G; Studt JD; Mendez A; Alberio L; Fontana P; Wuillemin WA; Schmidt A; Graf L; Gerber B; Bovet C; Sauter TC; Nagler M
Br J Haematol; 2021 Jun; 193(6):1203-1212. PubMed ID: 33954979
[TBL] [Abstract][Full Text] [Related]
13. Effect of Clarithromycin, a Strong CYP3A and P-glycoprotein Inhibitor, on the Pharmacokinetics of Edoxaban in Healthy Volunteers and the Evaluation of the Drug Interaction with Other Oral Factor Xa Inhibitors by a Microdose Cocktail Approach.
Lenard A; Hermann SA; Stoll F; Burhenne J; Foerster KI; Mikus G; Meid AD; Haefeli WE; Blank A
Cardiovasc Drugs Ther; 2023 Mar; ():. PubMed ID: 36870039
[TBL] [Abstract][Full Text] [Related]
14. Quantification of Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Serum by UHPLC-MS/MS-Method Development, Validation, and Application.
Lindahl S; Dyrkorn R; Spigset O; Hegstad S
Ther Drug Monit; 2018 Jun; 40(3):369-376. PubMed ID: 29578938
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine-A Multicenter Trial.
Harenberg J; Beyer-Westendorf J; Crowther M; Douxfils J; Elalamy I; Verhamme P; Bauersachs R; Hetjens S; Weiss C;
Thromb Haemost; 2020 Jan; 120(1):132-140. PubMed ID: 31705521
[TBL] [Abstract][Full Text] [Related]
16. Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation.
Lin SY; Kuo CH; Yeh SJ; Tsai LK; Liu YB; Huang CF; Tang SC; Jeng JS
Clin Pharmacol Ther; 2020 Jan; 107(1):278-286. PubMed ID: 31376150
[TBL] [Abstract][Full Text] [Related]
17. Measuring Direct Oral Anticoagulants.
Gosselin RC; Douxfils J
Methods Mol Biol; 2017; 1646():217-225. PubMed ID: 28804832
[TBL] [Abstract][Full Text] [Related]
18. Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
von Horn H; Rasmusson A; Söderblom L; Malmström RE; Antovic J
Int J Lab Hematol; 2022 Feb; 44(1):163-167. PubMed ID: 34523813
[TBL] [Abstract][Full Text] [Related]
19. A UHPLC-MS/MS method to simultaneously quantify apixaban, edoxaban and rivaroxaban in human plasma and breast milk: For emerging lactation studies.
Zhao Y; Couchman L; Kipper K; Arya R; Patel JP
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 May; 1144():122095. PubMed ID: 32251991
[TBL] [Abstract][Full Text] [Related]
20. DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register.
Cini M; Legnani C; Padrini R; Cosmi B; Dellanoce C; De Rosa G; Marcucci R; Pengo V; Poli D; Testa S; Palareti G
Int J Lab Hematol; 2020 Apr; 42(2):214-222. PubMed ID: 32039550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
